Skip to main content

Halozyme Therapeutics, Inc.

HALO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001159036

In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 673 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; no superinvestor holds it.

13F holders, Q2 2022

Institutional positions in Halozyme Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
368
+60 vs. Q1 2022
Shares held
128.3M
+586.0K (+0.5%) vs. Q1 2022
Total value
$5.65B
+$556.6M (+10.9%) vs. Q1 2022
New holders
86
126 more added
Sold out
26
114 more reduced

8 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q1 2022: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting HALO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2022: 368 institutions
Q1 2021: 337 institutionsQ2 2021: 315 institutionsQ3 2021: 326 institutionsQ4 2021: 326 institutionsQ1 2022: 316 institutionsQ2 2022: 368 institutionsQ3 2022: 357 institutionsQ4 2022: 423 institutionsQ1 2023: 387 institutionsQ2 2023: 370 institutionsQ3 2023: 390 institutionsQ4 2023: 411 institutionsQ1 2024: 413 institutionsQ2 2024: 460 institutionsQ3 2024: 510 institutionsQ4 2024: 509 institutionsQ1 2025: 550 institutionsQ2 2025: 552 institutionsQ3 2025: 604 institutionsQ4 2025: 619 institutionsQ1 2026: 637 institutionsQ2 2026: 673 institutions
Value heldQ2 2022: $5.65B
Q1 2021: $5.53BQ2 2021: $5.89BQ3 2021: $5.29BQ4 2021: $5.21BQ1 2022: $5.12BQ2 2022: $5.65BQ3 2022: $5.21BQ4 2022: $7.35BQ1 2023: $4.77BQ2 2023: $4.45BQ3 2023: $4.71BQ4 2023: $4.62BQ1 2024: $5.03BQ2 2024: $6.40BQ3 2024: $7.17BQ4 2024: $5.86BQ1 2025: $7.72BQ2 2025: $6.05BQ3 2025: $8.75BQ4 2025: $8.29BQ1 2026: $7.79BQ2 2026: $9.62B
Institutions holding HALO and their total value by quarter
QuarterHoldersValue
Q2 2026673$9.62B
Q1 2026637$7.79B
Q4 2025619$8.29B
Q3 2025604$8.75B
Q2 2025552$6.05B
Q1 2025550$7.72B
Q4 2024509$5.86B
Q3 2024510$7.17B
Q2 2024460$6.40B
Q1 2024413$5.03B
Q4 2023411$4.62B
Q3 2023390$4.71B
Q2 2023370$4.45B
Q1 2023387$4.77B
Q4 2022423$7.35B
Q3 2022357$5.21B
Q2 2022368$5.65B
Q1 2022316$5.12B
Q4 2021326$5.21B
Q3 2021326$5.29B
Q2 2021315$5.89B
Q1 2021337$5.53B

Institutions, Q2 2022

Shares, value and share of portfolio for each institution holding Halozyme Therapeutics, Inc.; share changes are against Q1 2022.

Institutions holding HALO in Q2 2022
InstitutionSharesValue% of portfolioChange in sharesAction
Teachers Retirement System of the State of Kentucky––––Not filed
SJS Investment Consulting Inc.––––Not filed